HC Wainwright Has Lowered Expectations for Assertio (NASDAQ:ASRT) Stock Price

Assertio (NASDAQ:ASRT) had its price target lowered by HC Wainwright from $4.00 to $3.50 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

ASRT has been the topic of a number of other reports. Industrial Alliance Securities set a $1.75 target price on shares of Assertio in a research report on Friday, March 14th. StockNews.com downgraded shares of Assertio from a “buy” rating to a “hold” rating in a research report on Monday, March 17th.

Assertio Trading Up 1.3 %

Shares of NASDAQ:ASRT opened at $0.72 on Wednesday. Assertio has a 52 week low of $0.68 and a 52 week high of $1.80. The company’s 50 day moving average is $0.80 and its two-hundred day moving average is $0.95. The company has a current ratio of 2.01, a quick ratio of 1.57 and a debt-to-equity ratio of 0.30. The company has a market cap of $68.96 million, a PE ratio of -0.99, a P/E/G ratio of 3.25 and a beta of 0.81.

Institutional Trading of Assertio

Hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors acquired a new stake in shares of Assertio in the 3rd quarter worth $26,000. Stifel Financial Corp acquired a new stake in shares of Assertio in the 4th quarter worth $27,000. Commonwealth Equity Services LLC acquired a new stake in shares of Assertio in the 4th quarter worth $30,000. Sonora Investment Management Group LLC acquired a new stake in shares of Assertio in the 4th quarter worth $39,000. Finally, Wealthfront Advisers LLC acquired a new stake in shares of Assertio in the 4th quarter worth $53,000. Institutional investors and hedge funds own 48.96% of the company’s stock.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.